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Abstract
Background: Therapeutic hypothermia (TH) has become standard care in newborns with moderate to severe
hypoxic ischemic encephalopathy (HIE), and the 2 most commonly used methods are selective head cooling (SHC)
and whole body cooling (WBC). This study aimed to determine if the effects of the 2 methods on some neural and
inflammatory biomarkers differ.
Materials and methods: This prospective randomized pilot study included newborns delivered after >36 weeks of
gestation. SHC or WBC was administered randomly to newborns with moderate to severe HIE that were prescribed
TH. The serum interleukin (IL)-1β, IL-6, neuron-specific enolase (NSE), brain-specific creatine kinase (CK-BB), tumor
necrosis factor-alpha (TNF-α), and protein S100 levels, the urine S100B level, and the urine lactate/creatinine (L/C)
ratio were evaluated 6 and 72 h after birth. The Bayley Scales of Infant and Toddler Development-III was
administered at month 12 for assessment of neurodevelopmental findings.
Results: The SHC group included 14 newborns, the WBC group included 10, the mild HIE group included 7, and
the control group included 9. All the biomarker levels in the SHC and WBC groups at 6 and 72 h were similar, and
all the changes in the biomarker levels between 6 and 72 h were similar in both groups. The serum IL-6 and
protein S100 levels at 6 h in the SHC and WBC groups were significantly higher than in the control group. The
urine L/C ratio at 6 h in the SHC and WBC groups was significantly higher than in the mild HIE and control groups.
The IL-6 level and L/C ratio at 6 and 72 h in the patients that had died or had disability at month 12 were
significantly higher than in the patients without disability at month 12.
Conclusion: The effects of SHC and WBC on the biomarkers evaluated did not differ. The urine L/C ratio might be
useful for differentiating newborns with moderate and severe HIE from those with mild HIE. Furthermore, the
serum IL-6 level and the L/C ratio might be useful for predicting disability and mortality in newborns with HIE.
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Background
Worldwide, hypoxic ischemic encephalopathy (HIE) is a
primary cause of disability and mortality in newborns
[1–7]. Currently, therapeutic hypothermia (TH) is rou-
tinely used to treat moderate and severe HIE [8–13]. TH
is administered as selective head cooling (SHC) or whole-
body cooling (WBC), but it is not known if the efficacy of
these 2 methods differ [14–19]. Regardless of which
method is used, it is recommended that TH be initiated
for HIE as early as possible, preferably within 6 h of birth
[9]. The diagnosis of HIE and making the decision to start
TH can be difficult. Furthermore, TH is not effective in all
cases of HIE and despite administration of TH severe dis-
ability can occur [1, 20]. As such, researchers have been
trying to identify a biomarker that can be used to diagnose
HIE, to determine if TH should be administered, and to
predict prognosis [21–23].
Earlier studies have reported some promising bio-
markers [21]. A recent study reported that TH adminis-
tered using WBC suppressed cytokine levels in newborns
with HIE, which was suggested to play a role in the neuro-
protective effect of TH [8]. This finding suggests that SHC
and WBC may have different effects on inflammatory and
neuronal biomarkers. To the best of our knowledge, no
study has compared the effect of SHC and WBC on bio-
markers; therefore, the present study aimed to determine
if the effects of these 2 methods on some neural and in-
flammatory biomarkers differ. An additional aim was to
determine if the studied biomarkers are useful for predict-
ing disability and mortality in newborns with HIE.
Methods
This prospective randomized study included newborns
born after >36 weeks of gestation that were inpatients at
Mersin University, School of Medicine, Neonatal Intensive
Care Unit, Mersin, Turkey, between April 2010 and
December 2011. The study protocol was approved by the
Mersin University Ethics Committee and written informed
consent was obtain from the families of the newborns.
During randomization, age >6 h, severe intrauterine
growth retardation, and congenial anomaly were consid-
ered exclusion criteria. HIE was diagnosed according to
American College of Obstetricians and Gynecologists cri-
teria [24], and modified Sarnat staging was used to classify
HIE [25]. Passive cooling (turning off the incubator heater
during transfer) was administered to newborns with HIE
that were transferred from other hospitals.
The decision to administer TH to the newborns with
HIE was based on having ≥1 of criteria A, B, and C, as
shown in Table 1. SHC or WBC was selected randomly via
the closed envelope method. SHC was administered using
a manually controlled device (Olympic Medical Cool Care
System, Olympic Medical, Seattle, WA, USA), whereas
WBC was administered using a room air conditioning
system. Body temperature was continuously monitored via
rectal probes in the SHC and WBC groups. In both groups
rectal temperature was recorded every 30 min. The tar-
geted 72-h rectal temperature for WBC was 33–34 °C, ver-
sus 34–35 °C for SHC. After the initial 72 h the rectal
temperature was increased for both TH methods to 36.5 °C
via increasing the temperature 0.5 °C h−1. Patients that were
not in the targeted temperature range for >1 h were
excluded.
Amplitude-integrated electroencephalography (aEEG)
findings were defined as severely abnormal based on con-
tinuous low voltage, burst suppression, or flat tracing in
the ground pattern, versus moderately abnormal based on
discontinuous normal voltage [26–28]. Newborns diag-
nosed as HIE that did not meet all the criteria for TH con-
stituted the mild HIE group. Newborns in the neonatal
intensive care unit with transient tachypnea, an Apgar
score >7 at 1 and 5 min, blood gas pH >7.30 within 1 h
after birth, and didn’t have clinical or culture positivity for
sepsis constituted the control group.
From all the included newborns 2 mL of blood and
2 mL of urine were collected 6 and 72 h after birth. The
blood samples were centrifuged, and then the separated
serum was stored at −80 °C until analyzed for interleukin
(IL)-6, IL-1β, tumor necrosis factor-alpha (TNF-α), brain-
specific creatine kinase (CK-BB), protein S100B via
enzyme-linked immunosorbent assay, and neuron-specific
enolase (NSE) and protein S100 via enzyme immunora-
diometric assay. Urine lactate and creatinine levels were
measured in fresh urine samples. Lactate was measured
via the colorimetric lactate oxidase method and creatinine
Table 1 Criteria indicative for therapeutic hypothermia
Criteria A
1. Apgar score <5 at 10 min of age
2. Continued need for ventilation 10 min after birth
3. pH <7.0 or base deficit < −16 in blood gases within 1 h of birth
Criteria B
Moderate to severe encephalopathy, consisting of altered state of
consciousness (as shown by lethargy, stupor, or coma) and >1 of the
following:
1. Hypotonia
2. Abnormal reflexes, including oculomotor or papillary
abnormalities
3. Absent or weak sucking reflex
4. Clinical seizures
Criteria C
Amplitude-integrated electroencephalography (aEEG) records (30-min)
1. Moderately abnormal aEEG background activity
2. Severely abnormal aEEG background activity
3. Seizure activity
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was measured via the enzymatic creatinine method, using
a Cobas Integra 800 analyzer (Roche Diagnostics).
The newborns were evaluated at age 12 months for
disability, neuromotor retardation, and mortality. Cogni-
tive, language, and motor development at 12 months
were evaluated using the Bayley Scales for Infant and
Toddler Development-III (BSID- III) [29]. Those with a
cognitive, language, or motor combined score 2 standard
deviations lower than the mean BSID-III score, total loss
of vision, or cerebral palsy were considered severely dis-
abled. Those with a cognitive, language, or motor com-
bined score 1 standard deviation lower than the BSID-III
mean were defined as neuromotor retardation. Those
with normal neurological examination findings without
audio or visual problems, and those with a cognitive,
language, and motor combined BSID-III score >85 were
considered disability free.
Statistical analysis
Statistical analysis was performed using PASW v.18.0 (Pre-
dictive Analytics Software, a registered trademark of SPSS,
Inc.) and Statistica v.8.0 (demo version). The distribution
of continuous variables was evaluated using the Shapiro-
Wilks test. Continuous variables with normal distribution
were compared between groups using one-way ANOVA
and the Scheffe post hoc test for multiple comparisons
was used to determine difference between groups. Con-
tinuous variables not normally distributed were compared
between groups using the Kruskal-Wallis test and Dunn
test. Findings at the 12-month evaluation were compared
between groups using the Mann–Whitney U test. The
Wilcoxon signed-rank test was used to compare findings
at 6 and 72 h within groups. The Fisher-Freeman exact
test was used when the expected value rule wasn’t ful-
filled, and the chi-square was used to evaluate the rela-
tionships between the categorical variables. Continuous
variables are shown as mean ± SD or median (IQR), de-
pending on the distribution. The level of statistical sig-
nificance was set at P < 0.05.
Results
During the study period, 54 newborns were diagnosed
as HIE, of which 11 were excluded because they were
aged >6 h at the time of randomization, 4 were ex-
cluded because died before 6 h, and 1 was excluded due
to a congenital malformation. Ten newborns not meet-
ing criteria for TH were included in the mild HIE
group. Of 28 infants meeting criteria for TH, 15 were
randomly allocated into group receiving SHC and 13
were allocated into group receiving WBC. One of the
newborns in the WBC group was later excluded from
the study because of the development of treatment-
resistant hypotension that resulted in discontinue of the
cooling therapy. In addition, serum and urine samples
were not timely collected in 1 patient in the SHC group, 2
patients in the WBC group, 3 patients in the mild HIE
group, and 1 case in the control group. After that the
SHC group included 14 patients, the WBC group included
10 patients, the mild HIE group included 7 patients and
the control group included 9 patients. The targeted rectal
temperature was maintained for 72 h in all the patients in
the SHC and WBC groups. Baseline patient characteristics
in the SHC and WBC groups were similar (p > 0.05). Base-
line patient characteristics in all groups are shown in
Table 2, and biomarker levels at 6 and 72 h are given in
Tables 3 and 4. The IL-6 level at 6 h was similar in the
SHC and WBC groups (P > 0.05), and was significantly
higher than in the control group (P = 0.026 for SHC-
control and P = 0.015 for WBC- control). The serum
protein S100 level at 6 h was similar in the SHC and
WBC groups (P > 0.05), and was significantly higher
than in the control group (P = 0.013 for SHC- control
and P = 0.031 for WBC- control). The L/C ratio at 6 h
was similar in the SHC and WBC groups (P > 0.05),
and was significantly higher than in the mild HIE
group (P = 0.008 for SHC- mild HIE and P = 0.014 for
WBC- mild HIE) and control group (P = 0.001 for
SHC- control and P = 0.002 WBC- control). The levels
of all the other biomarkers (serum IL-1β, TNF-α, NSE,
CKBB, and urine S100B) at 6 h were similar in each
group (P > 0.05). The IL-6 level at 72 h was similar in
the SHC and WBC groups (P > 0.05), and was signifi-
cantly higher than in the mild HIE group (P = 0.004 for
SHC- mild HIE and P = 0.003 for WBC- mild HIE) and
control group (P = 0.018 for SHC- control and P =
0.014 for WBC- control). The levels of all other bio-
markers at 72 h were similar in each group (P > 0.05).
The IL-6 level decreased significantly from 6 to 72 h
only in the mild HIE group (P = 0.028). The CK-BB
level decreased significantly from 6 to 72 h in all groups
(P < 0.05) and the L/C ratio decreased significantly from 6
to 72 h in the SHC (P = 0.008), WBC (P = 0.018), and con-
trol (P = 0.028) groups. The other biomarker levels did not
change significantly between 6 and 72 h in any of the
groups. Additionally, the difference between 6 and 72 h
for all the biomarkers was calculated in the SHC and
WBC groups in order to determine if the effect of the 2
methods differed; the increase or decrease in each bio-
marker between 6 and 72 h was determined in percent-
ages and there weren’t any significant differences between
the 2 groups (P > 0.05).
At the age 12 months evaluation in the SHC group
(n = 14) 5 of the patients had died, 5 were severely dis-
abled, 1 had neuromotor retardation, and 3 were dis-
ability free, whereas in the WBC group (n = 10) 5 of the
patients had died, 2 were severely disabled, and 3 were
disability free. At the age 12 months evaluation all 7 of
the patients in the mild HIE group were alive and
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Table 3 Biomarker levels at 6 h
Biomarkers SHC group (n = 14) WBC group (n = 10) Mild HIE group (n = 7) Control group (n = 9)
IL-6 (pg mL−1) 49.5a (15.8–219.9) 46.7a (33.1–413.5) 24.7a,b (14.0–69.6) 3.8b (2.8–6.6)
IL-1β (pg mL−1) 2.2 (2.1–2.3) 2.5 (2.1–3.0) 2.1 (2.0–2.6) 2.1 (2.0–2.2)
TNF-α (pg mL−1) 15.2 (10.8–25.6) 15.8 (13.7–41.6) 20.3 (13.9–25.6) 15.3 (13.1–24.4)
NSE (μg L−1) 0.58 (0.44–1.62) 0.67 (0.48–2.65) 0.49 (0.37–2.13) 0.45 (0.36–0.51)
S100B (ng mL−1) 0.08 (0.07–0.09) 0.12 (0.07–0.15) 0.11 (0.08–0.15) 0.07 (0.06–0.08)
S100 (ng L−1) 17.5a (5.6–60.4) 15.3a (7.7–86.9) 1.7a,b (0.8–25.6) 1.9b (0.7–4.7)
CKBB (ng mL−1) 1.9 (1.5–3.0) 2.1 (1.4–3.9) 1.9 (1.4–2.3) 1.4 (1.1–1.8)
L/C ratio 9.24a (1.32–43.89) 3.00a (0.82–34.60) 0.05b (0.03–0.11) 0.04b (0.03–0.08)
Data shown as median (IQR)
a and b denote differences between groups, according to post hoc test. There is a significant difference data shown with different letters (P < 0.05)
Table 2 Baseline patient characteristics
SHC (n = 14) WBC (n = 10) Mild HIE (n = 7) Control (n = 9) P
Gestational age (weeks) 38.6 ± 1.1 38.9 ± 1.0 38.8 ± 1.1 38.8 ± 0.8 0.931
Birth weight (g) 3183 ± 501 3218 ± 445 3410 ± 306 3081 ± 289 0.480
Head circumference (cm) 34.7 ± 1.1 34.7 ± 0.7 34.5 ± 1.0 34.6 ± 0.6 0.945
Male 4 (28.6) 3 (30.0) 2 (28.6) 4 (44.4) 0.905
Delivery via cesarean section 2 (14.3) 4 (40.0) 2 (28.6) 3 (33.3) 0.512
Birth in the treatment center 1 (7.1) a 0 (0.0) a 0 (0.0) a 7 (77.8) b <0.001
Age at group randomization (h) 5.4 ± 1.6 5.9 ± 0.3 5.3 ± 1.1 4.6 ± 1.9 0.225
Rectal temperature at group randomization (°C) 34.1 ± 0.9 34.4 ± 1.3 NA NA 0.615
Existence of clinical convulsions 13 (92.9) a 9 (90.0) a 0 (0.0) b 0 (0.0) b <0.001
Invasive mechanical ventilation 13 (92.9) a 9 (90.0) a 2 (28.6) b 0 (0.0) b <0.001
5-min Apgar score (n = 35)
0–3 5 (50.0) 4 (40.0) 0 (0.0) 0 (0.0)
4–6 5 (50.0) 6 (60.0) 5 (83.3) 0 (0.0)
7–10 0 (0.0) 0 (0.0) 1 (16.7) 9 (100)
10-min Apgar score (n = 24)
0–3 1 (14.3) 3 (75.0) 0 (0.0) 0 (0.0)
4–6 6 (85.7) 1 (25.0) 1 (25.0) 0 (0.0)
7–10 0 (0.0) 0 (0.0) 3 (75) 9 (100)
Blood gas analysis within 1 h post birth
pH 6.9 ± 0.2a 7.0 ± 0.1a 7.0 ± 0.1a 7.30 ± 0.1b 0.001
Base excess (mmol L−1) −17.7 ± 2.9a −19.6 ± 1.2a −17.8 ± 8.9a −2.6 ± 1.3b <0.001
aEEG before randomization
Normal 0 (0.0) 0 (0.0) 7 (100) NA <0.001
Moderate abnormality 3 (21.4) 1 (10.0) 0 (0.0) NA
Severe abnormality 11 (78.6) 9 (90.0) 0 (0.0) NA
Sarnat stage
Stage I 0 (0.0) 0 (0.0) 7 (100) NA <0.001
Stage II 3 (21.4) 1 (10.0) 0 (0.0) NA
Stage III 11 (78.6) 9 (90.0) 0 (0.0) NA
Values are given as median ± SD, or number of patients and percentage
a and b denote differences between groups, according to post hoc test. There is a significant difference data shown with different letters (P < 0.05)
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disability free. Among the 31 HIE patients in the study, at
age 12 months 18 were adverse outcomes (died, severe dis-
ability, or neuromotor retardation) and 13 were favorable
outcomes (living without disability). The serum IL-6 level
and urine L/C ratio at 6 and 72 h were significantly higher
in the patients that had adverse outcomes than in the
patients that had favorable outcomes at 12 months (IL-6:
P = 0.049 and P = 0.013, respectively; L/C ratio: P < 0.001
and P = 0.027, respectively). There weren’t any significant
relationships between the other 6th or 72nd hour bio-
marker levels and 12th month outcomes (Tables 5 and 6).
Discussion
In the present study there weren’t any differences between
the effects of SHC and WBC on the evaluated biomarkers
in newborns with moderate and severe HIE. The IL-6 level
and L/C ratio at 6 and 72 h in the patients that had died,
had severe disability, and had neuromotor retardation at
the time of the 12-month evaluation were significantly
higher than in those that were alive without disability at
month 12.
Although the precise mechanism of cellular damage
caused by hypoxia-ischemia remains unknown, energy
deficiency, excitatory neurotransmitters and free oxygen
radicals are considered to contribute to the cascade of
events leading to injury [30]. In addition, inflammation
is known to play an important role in the pathogenesis
of HIE [30]. Hypoxia-ischemia is followed by cerebral
and peripheral immune response. Microglia and astro-
cytes become activated on one hand, while peripheral
monocytes infiltrate the brain due to disrupted blood–
brain barrier on the other [8]. Activated inflammatory
cells release pro-inflammatory cytokines and chemo-
kines such as IL-1, IL-2, IL-6, IL-8, TNF-α, and inter-
ferons [8, 30]. As a result, inflammatory biomarkers’
levels increase in HIE. On the other hand, various
intracellular biomarkers like glial fibrillary acidic pro-
tein, NSE, and Protein S100 shift to extracellular com-
partment due to cell damage during HIE [31].
Researchers are trying to identify a biomarker suitable
for diagnosing HIE, and for predicting the severity of dis-
ease and prognosis in the early period. Many biomarkers in
blood, urine, and cerebrospinal fluid (CSF) have been stud-
ied, some of which were reported to be promising [21, 23].
The present study analyzed biomarkers that had been pre-
viously studied and were reported to be promising.
Nagdyman et al. [32] studied CK-BB, protein S100, and
NSE levels in cord blood and serum collected at 2, 6, 12,
and 24 h post birth in 7 newborns with moderate and se-
vere HIE, and in 22 with mild HIE. The protein S100 and
CK-BB levels in all the newborns with HIE at all time
points were significantly higher than in the control group.
Table 4 Biomarker levels at 72 h
Biomarkers SHC group (n = 14) WBC group (n = 10) Mild HIE group (n = 7) Control group (n = 9)
IL-6 (pg mL−1) 64.2a (30.4–118.0) 43.0a (33.1–416.0) 4.3b (1.2–17.6) 3.0b (1.3–6.0)
IL-1β (pg mL−1) 2.2 (2.0–2.3) 2.2 (2.1–2.6) 2.3 (2.1–2.7) 2.1 (2.0–2.2)
TNF-α (pg mL−1) 19.5 (12.5–41.7) 17.0 (13.3–25.3) 24.3 (20.2–40.6) 15.7 (10.8–16.7)
NSE (μg L−1) 0.51 (0.38–0.74) 0.57 (0.38–1.70) 1.01 (0.40–1.93) 0.38 (0.32–0.47)
S100B (ng/ml 0.08 (0.07–0.15) 0.10 (0.06–0.15) 0.12 (0.07–0.21) 0.08 (0.07–0.12)
S100 (ng L−1) 2.9 (0.5–15.5) 9.5 (0.3–29.8) 1.6 (0.8–3.6) 1.5 (0.4–3.8)
CKBB (ng mL−1) 1.0 (0.6–1.7) 0.8 (0.5–1.5) 0.9 (0.7–1.1) 1.0 (0.8–1.1)
L/C ratio 0.08 (0.04–0.27) 0.06 (0.04–0.16) 0.05 (0.03–0.06) 0.03 (0.02–0.04)
Data shown as median (IQR)
a and b denote differences between groups, according to post hoc test. There is a significant difference data shown with different letters (P < 0.05)
Table 5 The relationship between biomarker levels at 6 h and outcomes at age 12 months
Biomarkers Patients with adverse outcomes (n = 18) Patients with favorable outcomes (n = 13)
IL-6 (pg mL−1) 121.1 (31.4–334.3)* 33.2 (13.0–61.7)
IL-1β (pg mL−1) 2.3 (2.1–2.5) 2.3 (2.0–2.5)
TNF-α (pg mL−1) 16.6 (10.8–32.7) 16.5 (13.3–21.0)
NSE (μg L−1) 0.55 (0.44–1.10) 1.31 (0.46–2.15)
S100B (ng mL−1) 0.08 (0.06–0.13) 0.08 (0.07–0.15)
S100 (ng L−1) 13.5 (5.8–31.0) 22.4 (1.3–136.4)
CKBB (ng mL−1) 2.1 (1.5–3.5) 1.9 (1.4–2.4)
L/C ratio 19.0 (2.64–47.89)* 0.12 (0.04–0.36)
Data shown as median (IQR)
*There is a significant difference between groups (P < 0.05)
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In addition, the serum protein S100 and CK-BB levels at 2
and 6 h were significantly higher in the newborns with
moderate and severe HIE than in those with mild HIE.
There wasn’t a significant difference in the serum NSE
level between the newborns with HIE and the control
group at any time point. Similarly, in the present there
wasn’t a significant difference in the serum NSE level be-
tween the newborns with HIE and the control group.
Additionally, the protein S100 level at 6 h was significantly
higher in the newborns with moderate and severe HIE
(SHC and WBC) than in the control group. Moreover, in
contrast to Nagdyman et al.’s [30] study there wasn’t a sig-
nificant difference in the serum CK-BB level between the
present study’s newborns with and without HIE, which
might be because TH was administered in the present
study’s newborns with moderate and severe HIE, but not
in Nagdyman et al.’s patients.
Gazzolo et al. [33] studied the urine S100B level at 0, 24,
48, and 96 h in newborns with HIE and healthy controls.
They reported that the urine S100B level in the newborns
with HIE that died at age 1–7 d (n = 12) was significantly
higher than in those that were alive on d 7 (n = 48) and
the control group (n = 72). In the present study the urine
S100B level was similar in the SHC, WBC, mild HIE, and
control groups, and a non-significant correlation was ob-
served between the adverse outcomes at month 12, and
the S100B level at 6 and 72 h. The difference in findings
between the present study and Gazzolo et al.’s might be
due to administration of TH in the present study. More-
over, an earlier study [34] reported that the S100B level
was significantly lower in newborns with HIE treated with
TH than in newborns with similar properties with HIE
that weren’t treated with TH.
Huang et al. [35] studied the urine L/C ratio at 6 and
48–72 h in 40 newborns with HIE and 58 healthy con-
trols. They observed that the urine L/C ratio was signifi-
cantly higher in the newborns with HIE and the mean
ratio of urinary L/C was significantly higher in the infants
who had adverse outcomes (death, severe cerebral palsy,
BSID II score that was more than 2 SD below the mean
score for age, blindness, or deafness) at month 12 than the
infants with favorable outcomes (normal neurologic devel-
opment or slight abnormalities in muscle tone and re-
flexes). A similar study by Ghotbi et al. [36] reported that
the L/C ratio at 6 and 24 h was significantly higher in 50
newborns with HIE than in 50 healthy controls. In the
present study TH was administered in newborns with
moderate and severe HIE, in contrast to the other studies,
and the L/C ratio was observed to be significantly higher
in the newborns with moderate and severe HIE than in
those in the mild HIE and control groups. Furthermore,
the L/C ratio was higher at 6 and 72 h in the present
study’s patients that had died, had severe disability, and
had neuromotor retardation at month 12 than in those
that were living without disability, as reported by Huang
et al. [35]. These findings suggest that the urine L/C ratio
might be useful for identifying newborns with moderate
and severe HIE, and for predicting disability and mortality.
Massaro et al. [9] studied the serum NSE and S100B
levels at 0, 12, 24, and 72 h of hypothermia in newborns
with HIE that received TH using WBC and their relation-
ship to neurodevelopmental results. They reported that
there was a significant relationship between serum NSE
and S100B levels, and neurodevelopmental results at
month 15. In the present study there wasn’t a significant
relationship between adverse outcomes month 12, and
NSE or S100B levels at 6 and 72 h. It is possible that these
different results may be due to the heterogeneity of the
etiologies that lead to HIE, timing of the insult and vari-
ability of the severity.
Chalak et al. [20] administered WBC in 20 newborns
with moderate and severe HIE, but not in 7 with mild
HIE. They analyzed various neuronal and inflammatory
biomarkers in the blood samples obtained at 6–24, 48,
72, and 78 h. They reported that the IL-6 level at 6–24 h
was significantly higher in the newborns with moderate
and severe HIE than in those with mild HIE. Further-
more, they noted that there was a significant relationship
Table 6 The relationship between biomarker levels at 72 h and outcomes at age 12 months
Biomarkers Patients with adverse outcomes (n = 18) Patients with favorable outcomes (n = 13)
IL-6 (pg mL−1) 60.3 (29.1–121.1)* 24.6 (3.9–45.0)
IL-1β (pg mL−1) 2.1 (2.0–2.2) 2.3 (2.1–2.7)
TNF-α (pg mL−1) 17.7 (12.2–41.3) 22.8 (15.7–31.9)
NSE (μg L−1) 0.52 (0.38–0.74) 0.98 (0.44–2.13)
S100B (ng mL−1) 0.09 (0.06–0.12) 0.11 (0.07–0.21)
S100 (ng L−1) 1.9 (0.4–15.8) 3.5 (0.7–20.1)
CKBB (ng mL−1) 0.8 (0.6–1.5) 1.0 (0.7–1.3)
L/C ratio 0.13 (0.04–0.26)* 0.04 (0.03–0.06)
Data shown as median (IQR)
*There is a significant difference between groups (P < 0.05)
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between the IL-6 and TNF-α levels at 6–24 h, and ab-
normal neurological results at 15–18 months. In the
present study the IL-6 level at 6 h was significantly
higher in the SHC and WBC groups than in the control
group, and the IL-6 level at 72 h was significantly higher
in the SHC and WBC groups than in the mild HIE and
control groups. As reported by Chalak et al. [20], the IL-
6 level at 6 and 72 h in the present study’s patients that
had died, had severe disability, and had neuromotor re-
tardation at month 12 was significantly higher than in
those that were living without disability. In contrast to
Chalak et al. [20], in the present study there wasn’t a
correlation between the TNF-α level at 6 and 72 h, and
adverse outcomes at month 12.
Roka et al. [8] performed a study to determine if TH
causes a change in serum cytokine levels in newborns
with HIE. They administered WBC in 10 newborns
with moderate and severe HIE, but didn’t administer
WBC in 8 newborns with moderate and severe HIE.
The newborns with HIE that did and did not receive
WBC were compared in terms of serum cytokine levels
at 6, 12, and 24 h after birth. They reported that the IL-
6 level at 6 h was significantly lower in the WBC group
than in the non-WBC group. They suggested based on
this result that TH rapidly suppresses cytokine produc-
tion as a response to asphyxia and that this might be an
important mechanism associated with the neuroprotec-
tive effect of TH. In the present study SHC or WBC
was administered to each newborn with moderate and
severe HIE, as withholding such treatment would have
been unethical. Following TH, there weren’t any signifi-
cant differences regarding change in the biomarker
levels between the 2 methods. The IL-6 level at 6 h was
significantly higher in the newborns with HIE (SHC,
WBC, and mild HIE groups) than in the control group,
which supports the notion that cytokines increase sec-
ondary to asphyxia. Moreover, there wasn’t a significant
change in the IL-6 level from 6 to 72 h in the SHC or
WBC groups, whereas the IL-6 level at 72 h was signifi-
cantly lower than at 6 h in the mild HIE group even
though TH wasn’t administered. This finding suggests
that even if TH suppresses cytokine production, it can’t
decrease the cytokine level to normal within 72 h of
birth in newborns with moderate or severe HIE.
The most important limitation of the present study is
the small study population; however, to the best of our
knowledge this prospective, randomized single-center
study is the first to compare the effects of SHC and
WBC on biomarker levels in newborns with HIE. An-
other limitation is that biomarkers in CSF weren’t ana-
lyzed; had they been the findings might have differed.
The biomarker levels were measured only in serum and
urine samples, as they are more useful and their collec-
tion in less invasive.
Conclusion
There weren’t any differences in the effects of SHC and
WBC on the biomarkers evaluated in the present study.
Serum IL-6 and protein S100 levels may be useful for
diagnosing HIE, and the urine L/C ratio may be useful
for differentiating newborns with moderate and severe
HIE from those with mild HIE. The serum IL-6 level
and the L/C ratio might also be useful for identifying
cases of HIE that might result in disability or mortality.
Additional larger scale and longer term studies might
yield more generalizable findings.
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